<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216720</url>
  </required_header>
  <id_info>
    <org_study_id>1-16-02-188-17</org_study_id>
    <nct_id>NCT03216720</nct_id>
  </id_info>
  <brief_title>Miniaturized Extracorporeal Circulation Study</brief_title>
  <official_title>The Impact of Miniaturized Extracorporeal Circulation on Thrombin Generation and Postoperative Blood Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Contemporary coronary artery bypass grafting (CABG) continues to be associated with a
      significant risk of postoperative bleeding. Utilization of miniaturized extracorporeal
      circulation (miECC) significantly reduces the risk of postoperative bleeding but the
      underlying mechanisms are poorly understood.

      Primary Objective:

      To assess the impact of miECC compared to conventional extracorporeal circulation (cECC) on
      thrombin generation as indicator of the overall haemostatic capacity after CABG.

      Secondary Objectives To evaluate the impact of miECC versus cECC on blood loss and
      transfusion requirement, coagulation and fbrinolysis, inflammatory response, haemodilution
      and haemolysis, endorgan protection, seasibility and safety

      Study design:

      Single-center, double-blind, parallel-group randomized controlled trial

      Study population:

      60 Patients undergoing non-emergent primary isolated CABG with ECC randomized 1:1 to receive
      either miECC or cECC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples will be obtained at the following time points:

        -  T0; preoperative after induction of anaesthesia (after insertion of central venous line)

        -  T1; after weaning of the ECC prior to protaminization

        -  T2; 10 minutes after full protaminization

        -  T3; six hours after the end of the ECC

        -  T4; 1. postoperative day (16-20 hours following end of surgery)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative thrombin generation</measure>
    <time_frame>up to 6 hours after CABG</time_frame>
    <description>Thrombin generation as a measure of the ability to generate thrombin in platelet poor plasma. Derived from the thrombogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative blood loss</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>Total output of mediastinal and pleural chest tubes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative transfusion requirement</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Transfusion of red blood cells, fresh frozen plasma, platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinolysis (Clot lysis, Fibrin D-dimer)</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>Clot lysis measured by dynamic turbidimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation tests</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>Platelet Count
aPTT
INR
Antithrombin
Fibrinogen
Prothrombin fragment 1+2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>TNF-α
Interleukin panel
CRP white blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodilution (Nadir intraoperative haematocrit)</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>Measured in arterial blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemolysis (LDH)</measure>
    <time_frame>up to 24 hours postoperative</time_frame>
    <description>Measured in lithium heparin plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative CK-MB for myocardial injury</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>Measured in lithium heparin plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Intraoperative blood lactate for inadequate tissue perfusion</measure>
    <time_frame>up to 24 hours after CABG</time_frame>
    <description>Measured in arterial blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative creatinine clearance for renal injury</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Creatinine measured in lithium heparin plasma. eGFR calculated according to the CKD EPI Equation for Estimating GFR Expressed for Specified Race, Sex and Serum Creatinine (µmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Perioperative myocardial infarction</measure>
    <time_frame>48 hours after CABG</time_frame>
    <description>defined according to the new definition of clinically relevant MI of the Society for Cardiovascular Angiography and Interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-In-hospital neurological events (TCI/stroke)</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>verified by CT or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Postoperative requirement of renal replacement therapy</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Continuous or intermittend renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Postoperative re-exploration for bleeding</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Re-exploration due to excessive bleeding or haemodynamic instability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Repeat revascularization</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Defined as unplanned repeat PCI or CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Length of ICU stay</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Days of stay on ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Duration of inotropic support</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Hours of pharmacological or mechanical circulatory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Incidence of atrial fibrillation</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Documented by telemetry or ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Incidence of infection (requiring antibiotic therapy, wound revision for graft leg infection, superficial or deep sternal wound infection)</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Deep sternal wound infection
Wound revision for leg harvest surgical site infection
Requirement of antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Feasibility of miECC as measured by conversion to cECC and intraoperative complications</measure>
    <time_frame>24 hours</time_frame>
    <description>Serious adverse device events (air lock, dissection, bleeding that exceeds the capacity of the cell saver, air emboli, stop of the circuit, conversion to cECC)
- technical aspects (postoperative fluid gain (ml), venous drainage, visibility due to blood in the operative field, ability to maintain SvO2 &gt;65%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-30-day MACCE</measure>
    <time_frame>up to 30 days after CABG</time_frame>
    <description>Death
MI
cerebrovascular accident
repeat revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CABG with miniaturized ECC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG with conventional ECC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elective CABG with conventional extracorporeal circulation (cECC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <description>Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula
Grafting: pedicled left internal mammary artery, and no-touch
saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System
Target activated coagulation time of &gt;400 seconds</description>
    <arm_group_label>CABG with miniaturized ECC</arm_group_label>
    <arm_group_label>CABG with conventional ECC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Miniaturized extracorporeal circulation</intervention_name>
    <description>Centrifugal pump to reduce mechanical stress
Circuit coated with biosurface to increase haemocompatibilty.
Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution
Collapsible soft-shell reservoir for blood volume management
Cell-saving device
Venous air removing device and electric clamp system to air embolism</description>
    <arm_group_label>CABG with miniaturized ECC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional extracorporeal circulation</intervention_name>
    <description>Roller pump
Circuit uncoated
Hard-shell venous reservoir
Intermittend cold blood Harefield cardioplegia</description>
    <arm_group_label>CABG with conventional ECC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-emergent CABG with ECC

          -  Current use of low-dose acetylsalicylic acid

          -  Agreement of eligibility by the multidisciplinary heart team

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Emergent treatment required (&lt; 24 hours)

          -  Concomitant cardiac surgery

          -  Previous cardiac surgery

          -  Severely reduced kidney function (eGFR &lt; 30ml/min/1.73m2 or on dialysis)

          -  Severely reduced ejection fraction (EF &lt; 45%)

          -  Diagnosis of bleeding disorders

          -  Non-aspirin antiplatelet drugs stopped &lt; 5 days preoperatively (Clopidogrel,
             Prasugrel, Ticagrelor, Ticlopidine)

          -  Current use of systemic glucocorticoid therapy

          -  Current use of vitamin K antagonists or new oral non-vitamin K anticoagulants

          -  Platelet count &gt; 450 or &lt;100 x 109/l prior to surgery

          -  Pregnant women or women of child bearing potential without negative pregnancy test

          -  Active participant in any other intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivy Susanne Modrau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital Skejby</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivy Susanne Modrau, MD</last_name>
    <phone>+45 24778856</phone>
    <email>ivy.modrau@skejby.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Mette Hvas, MD</last_name>
    <phone>+45 2118 6893</phone>
    <email>annehvas@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivy Susanne Modrau, MD</last_name>
      <phone>+45 24778856</phone>
      <email>ivy.modrau@skejby.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Anne Mette Hvas, MD</last_name>
      <phone>+45 21186893</phone>
      <email>annehvas@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Ivy Susanne Modrau</investigator_full_name>
    <investigator_title>Consultant Cardiac Surgeon, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery bypass grafting</keyword>
  <keyword>Miniaturized extracorporeal circulation</keyword>
  <keyword>Thrombin generation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

